CD86 and neoplasm: In the immune-resistant tumor model, these RNA NPs activated high levels of PDL1+ CD86+ myeloid cells, indicating that extensive immune activation of tumor-loaded RNA-NPs, accompanied by inducible PD-L1 expression, could be used for treatment.